Tagged with

Opinion Aditya Bhattacharji takes a look at the potentially damaging impact of political uncertainty across Europe – including the impending exit of the UK from the European Union – on pharmaceutical firms across the continent.   The right-leaning parties that will play a more prominent role in European politics are even…

Europe The European MidPharma Performance Ranking 2019 is taken from The Novasecta European Midpharma Report 2019, which examines how European mid-cap pharma companies are surviving and thriving. With scores assigned to R&D investment, commercial revenues and business development, this is a comprehensive list of the recent performance of some of Europe’s…

Opinion David H. Crean highlights R&D efforts and ongoing investments in Alzheimer’s disease treatments as we enter the month of June, brain awareness month.   Alzheimer’s disease is a complex chronic disease characterized biologically by the accumulation of extracellular protein plaques, neurofibrillary protein tangles, a loss of functional synaptic connections, and eventually…

China On May 30th, and with much fanfare, Pfizer Upjohn officially inaugurated its global headquarters in the heart of Shanghai, China. Following a global re-organization mid-2018, Pfizer now operates three business units, namely Innovative Medicines (including biosimilars and a new hospital business unit dealing with anti-infectives and sterile injectables), Consumer Healthcare,…

China Carsten Lu of Chinese biotech Adlai Nortye outlines his strategy for navigating a crowded immuno-oncology field in China, his partnership strategy, and the firm’s early move to establish a footprint in the USA.   The Chinese biotech industry itself is already moving at supersonic speeds to catch up to international…

USA David Bearman makes the historical case to be once again considered as a medicine across the USA, noting that economic – rather than health – concerns were behind the creation of the Marijuana Tax Act of 1937 and continue to persist to this day.   With all this history, why…

Taiwan Dar-Bin Shieh, deputy minister of science and technology of the Republic of China (Taiwan), gives an overview of Biomedical Industry Innovation Program, enacted to bolster Taiwan’s biomedical and biotechnology sectors as part of the 5+2 Industrial Innovation Plan. Deputy Minister Shieh also elaborates on how Taiwan’s unique strengths in ICT,…

Egypt Dr Wafik Bardissi, chairman and CEO of Minapharm, the only company to offer biosimilars in Egypt, highlights how the company has successfully developed biotech know-how by partnering with and acquiring German companies. He also emphasizes the need for more local manufacturing and improving biosimilar infrastructure in Egypt.   As Minapharm…

Taiwan Taiwan boasts one of the most sophisticated and comprehensive public health systems in Asia. However, mounting costs and the pressures of a rapidly ageing population mean that the National Health Insurance (NHI) system may run out of money within the next two years without significant reform.   NHI expenditures have…

Taiwan Taiwan’s Minister of Economic Affairs, Jong-Chin Shen, outlines the initiatives implemented by the Ministry to help Taiwan’s industries reinforce their competitive advantage. Minister Shen also goes on to explain the Ministry’s specific role within the Biomedical Industry Innovation Promotion Program under the administration’s 5+2 Innovative Industries Policy.   Taiwan’s investment…

Spain Jaime Vives, managing director of Roche Diagnostics in Spain, discusses the digital solutions Roche Diagnostics is trying to roll out in Spain, the challenges involved, and the potential implications of digitalising healthcare   The first step into digitalization is to convince our customers to standardise their systems and the way…

Algeria Yacine Sellam, president of the Algerian Society for Regulatory Affairs & Pharmacoeconomics, examines Algeria’s recent issues around medicine shortages, its root causes, and the measure being taken to counter it.   The smooth operation of the drug distribution chain in Algeria is compromised by its multiplicity of actors – from…